TRCT
VERV

Tower Research Capital (TRC)’s Verve Therapeutics VERV Stock Holding History

Tower Research Capital (TRC)’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-8,773
Closed -$98.5K – 5654
2025
Q2 		$98.5K Buy
8,773
+4,884
+126% +$27.8K ﹤0.01% 2389
2025
Q1 		$17.8K Sell
3,889
-9,508
-71% -$63.7K ﹤0.01% 3091
2024
Q4 		$75.6K Sell
13,397
-12,890
-49% -$72.7K ﹤0.01% 2319
2024
Q3 		$127K Buy
26,287
+1,525
+6% +$8.86K ﹤0.01% 2039
2024
Q2 		$121K Buy
24,762
+23,521
+1,895% +$148K ﹤0.01% 2446
2024
Q1 		$16.5K Sell
1,241
-148
-11% -$1.96K ﹤0.01% 3177
2023
Q4 		$19.4K Sell
1,389
-732
-35% -$9.07K ﹤0.01% 3668
2023
Q3 		$28.1K Sell
2,121
-1,428
-40% -$23K ﹤0.01% 3069
2023
Q2 		$66.5K Sell
3,549
-2,784
-44% -$46.4K ﹤0.01% 2344
2023
Q1 		$91K Buy
6,333
+359
+6% +$7.03K ﹤0.01% 1960
2022
Q4 		$116K Sell
5,974
-165
-3% -$4.37K ﹤0.01% 1723
2022
Q3 		$211K Buy
6,139
+3,815
+164% +$122K ﹤0.01% 1879
2022
Q2 		$35K Sell
2,324
-1,500
-39% -$23.2K ﹤0.01% 3225
2022
Q1 		$87K Sell
3,824
-2,025
-35% -$57.9K ﹤0.01% 2319
2021
Q4 		$216K Buy
5,849
+4,749
+432% +$200K ﹤0.01% 1707
2021
Q3 		$52K Buy
+1,100
New +$64.7K ﹤0.01% 2938

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Tower Research Capital (TRC)'s VERV Position: Q3 2025 in Review

Tower Research Capital (TRC) sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 8,773 shares — an estimated $98.5K sold.

Tower Research Capital (TRC) first reported a position in VERV in Q3 2021 and held it in 16 quarters. The position peaked at $216K in Q4 2021. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Tower Research Capital (TRC) reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 8,773 Verve Therapeutics shares in Q3 2025, an estimated $98.5K.
  • Tower Research Capital (TRC) first reported a position in Verve Therapeutics in Q3 2021 and held it in 16 quarters.
  • Tower Research Capital (TRC)'s Verve Therapeutics position peaked at $216K in Q4 2021.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2025, filed 14 Nov 2025.